Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 1
1968 1
1969 1
1970 1
1976 1
1979 2
1982 2
1983 2
1984 1
1985 1
1986 2
1987 1
1988 1
1989 2
1990 5
1992 3
1993 2
1995 2
1997 4
1998 3
1999 2
2000 3
2001 3
2002 1
2003 1
2004 2
2005 2
2006 2
2007 4
2008 3
2009 5
2010 1
2011 2
2012 4
2013 2
2014 11
2015 13
2016 13
2017 12
2018 11
2019 14
2020 12
2021 17
2022 14
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Results by year

Filters applied: . Clear all
Page 1
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Byrd JC, et al. Among authors: harrington b. N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7. N Engl J Med. 2016. PMID: 26641137 Free PMC article. Clinical Trial.
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, Awan FT, Maddocks K, Andritsos L, Lehman AM, Sampath D, Lapalombella R, Eathiraj S, Abbadessa G, Schwartz B, Johnson AJ, Byrd JC, Woyach JA. Reiff SD, et al. Among authors: harrington bk. Cancer Discov. 2018 Oct;8(10):1300-1315. doi: 10.1158/2159-8290.CD-17-1409. Epub 2018 Aug 9. Cancer Discov. 2018. PMID: 30093506 Free PMC article.
Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
Walker JS, Hing ZA, Harrington B, Baumhardt J, Ozer HG, Lehman A, Giacopelli B, Beaver L, Williams K, Skinner JN, Cempre CB, Sun Q, Shacham S, Stromberg BR, Summers MK, Abruzzo LV, Rassenti L, Kipps TJ, Parikh S, Kay NE, Rogers KA, Woyach JA, Coppola V, Chook YM, Oakes C, Byrd JC, Lapalombella R. Walker JS, et al. Among authors: harrington b. J Hematol Oncol. 2021 Jan 15;14(1):17. doi: 10.1186/s13045-021-01032-2. J Hematol Oncol. 2021. PMID: 33451349 Free PMC article.
NF-κB Signaling in Ovarian Cancer.
Harrington BS, Annunziata CM. Harrington BS, et al. Cancers (Basel). 2019 Aug 15;11(8):1182. doi: 10.3390/cancers11081182. Cancers (Basel). 2019. PMID: 31443240 Free PMC article. Review.
Socks and all.
Harrington BH. Harrington BH. Am J Nurs. 2011 Jan;111(1):72. doi: 10.1097/01.NAJ.0000393071.37127.e8. Am J Nurs. 2011. PMID: 21191245 No abstract available.
Clonal hematopoiesis of indeterminate potential in the companion dog.
Sebastian K, Özer HG, Howard C, Chadsey L, Lozanski A, Doong TJ, Orwick S, Lozanski G, Ma W, Kisseberth WC, Byrd JC, Harrington BK. Sebastian K, et al. Among authors: harrington bk. Leukemia. 2022 May;36(5):1401-1403. doi: 10.1038/s41375-022-01520-5. Epub 2022 Feb 10. Leukemia. 2022. PMID: 35145204 No abstract available.
Doctors and management.
Harrington B. Harrington B. BMJ. 1995 Feb 18;310(6977):469. doi: 10.1136/bmj.310.6977.469b. BMJ. 1995. PMID: 7873973 Free PMC article. No abstract available.
176 results